Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis
Open Access
- 5 July 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in npj Vaccines
- Vol. 7 (1), 1-4
- https://doi.org/10.1038/s41541-022-00491-z
Abstract
We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3–6 months after the initial hospital admissions. Patient outcomes ranged from good recovery (13 patients, 29.6%) to moderate disability (11 patients, 25.0%) and severe disability or vegetative state (6 patients, 13.6%). Fatal outcomes were reported in 14 patients (31.8%).Keywords
This publication has 16 references indexed in Scilit:
- Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus ThrombosisJAMA Cardiology, 2021
- Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic ThrombocytopeniaStroke, 2021
- COVID‐19 Vaccine‐Associated Cerebral Venous Thrombosis in GermanyAnnals of Neurology, 2021
- Diagnosis and Management of Cerebral Venous Sinus Thrombosis With Vaccine-Induced Immune Thrombotic ThrombocytopeniaStroke, 2021
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 VaccinationThe New England Journal of Medicine, 2021
- Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” ExposureJournal of Clinical Medicine, 2021
- Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTHHämostaseologie, 2021
- Prognosis of Cerebral Vein and Dural Sinus ThrombosisStroke, 2004